Michelle Chung is a Venture Partner with Panacea. Michelle has over 30 years of healthcare industry experience with significant commercial expertise encompassing senior marketing, new product planning/lifecycle and sales leadership roles across a variety of therapy areas.

Prior to joining Panacea, Michelle was Vice President of Marketing at Braeburn, a specialty biopharmaceutical company focused on the treatment of opioid addiction. Before that, Michelle served as Global Senior Director of COPAXONE for MS at Teva Pharmaceuticals, launched two pain management treatments at Iroko Pharmaceuticals and served as Senior Marketing Director at Anesiva, a biopharmaceutical company focused on pain management.  Michelle also led the successful launch of the Type 2 Diabetes treatments, Avandia in the UK and Avandamet in the US while at GlaxoSmithKline.

Michelle holds a B.A. degree in Communications from Villanova University.

Katherine Cohen joined Panacea Venture in 2018 and is based in Vienna, Austria.  She has over 25 years of experience in the biotech and pharmaceutical industry and is a certified European Patent Attorney.  Before joining Panacea Venture, Dr. Cohen served as CEO at Hookipa Biotech AG (now Hookipa Pharma Inc.), where she was responsible for the company formation and Series A and B venture financing, and under her leadership Hookipa grew from a research start-up to a clinical stage company.  Prior to Hookipa, Dr. Cohen was Senior Vice President for Corporate and Business Development at Intercell AG (now Valneva SE) where she played an important role in the growth of the company from a start-up to a successful public and commercial stage enterprise.  Prior to her biotech entrepreneurial career, Dr. Cohen worked in academic research and industrial development at Sandoz/VIRCC.

Dr. Cohen earned her Ph.D. in Biology at the City University of New York and B.S. from Wuhan University in China.

Nancy Donahue is a Venture Partner with Panacea. Nancy has over 30 years of experience in the healthcare industry, with significant commercial expertise covering sales, marketing, and executive leadership. 

Prior to joining Panacea, Nancy was Vice President of Marketing at Braeburn, a specialty biopharmaceutical company focused on the treatment of opioid addiction. Before that, Nancy served as Global Senior Director of COPAXONE at Teva Pharmaceuticals and launched two pain management treatments at Iroko Pharmaceuticals. Nancy also served as Senior Vice President of Sales and Marketing at Anesiva, where she built and led the commercial organization. Nancy started her career at GlaxoSmithKline and during her 15-year tenure, she led the diabetes franchise and launched and grew Coreg into a billion-dollar cardiovascular brand.

Nancy holds a B.S. degree in Food Marketing from Saint Joseph's University.

Jimmy Lu is a Venture Partner with Panacea. Jimmy has over 35 years of venture capital, healthcare & high technology and general business / legal experience. Prior to joining Panacea, Jimmy worked at WI Harper Group as a managing director and senior partner. Jimmy also previously worked as a managing director and general partner at Acer Technology Ventures & iD Ventures and the General Counsel at The Acer Group.

Jimmy received a J.D. from the University of California, Berkeley, School of Law an M.B.A from Harvard University and a B.A. from Yale College.

Hai was a partner at Kleiner Perkins Caufield & Byers China before he co-founded Panacea Venture with his partner James Huang.  Prior to joining KPCB China, Hai was a partner DT Capital responsible for investment in life science and healthcare, and a venture partner of SB China Venture Capital (SBCVC).  His investment includes BGI Tech, Symap Medical, Precise Light, and NeuInvent Inc.

Hai was Senior Director of Strategic Planning and then Vice President of Corporate Communications at WuXi AppTec in Shanghai, he also served on the board of Chemspec International (NYSE: CPC) as an independent board director and the chairman of audit committee.  Earlier Dr. Mi was a research scientist at Parke-Davis Pharmaceuticals and then a senior manager at Pfizer in US.

Hai obtained a Ph.D. in organic chemistry from New York University, an MBA from The University of Chicago Booth School of Business, and a B.S. in material science from Fudan University in Shanghai.

Rosemary Mazanet MD, PhD is a Venture Partner with Panacea Venture. Dr. Mazanet is a well-known investor and C-suite professional in Biotech.  Trained as an internist and oncologist in the Harvard Hospitals, she moved to Amgen, Inc. in the 1990s where she led Clinical Development teams that conducted successful development programs leading to global product approvals.  She subsequently moved to apply her expertise to the public equity markets in NY (Oracle Partners, Apelles LP Argenis LP), where she often supported portfolio company Management teams and served as a Director.  She continues that consulting work currently through R Mazanet LLC, and currently serves as CSO or CMO for early stage companies.  

In addition to being an Independent Director on corporate boards, she is an Emeritus Trustee at the University of Pennsylvania Health System (her alma mater) as well as serving as the Chair, Executive Advisory Board for the Wharton Leonard Davis Institute.  She sits on the Executive Committee of Save Venice, Boston.

Dr Tang was most recently a Medical Officer and Clinical Reviewer in the General Medicine Branch of the Office of Tissue and Advanced Therapy, Center for Biologics Evaluation and Research, the United States Food and Drug Administration. As a Medical Officer, he was responsible for regulating submissions related to gene and cell therapies, polyclonal antibodies, selected vaccines and combination products. He specialized in the regulation of gene and immune therapies, stem cell therapies and orphan diseases. He has reviewed submissions covering all stages of clinical development from the pre-Pre IND (currently referred to as Interact) stage to Biologic License Applications. In addition to his review work, he also served on a FDA sponsored working group for renal replacement therapy (including xenotransplantation), coauthored a guidance document for genome editing (2018), and was involved in outreach activities with the biotech industry. Dr Tang was the recipient of the CBER Regulatory Scientist Achievement Award in 2017. 

Han Ying is a Venture Partner with Panacea. Dr. Ying is a 20-year biotech veteran specializing in cell therapy. He received postdoctoral training with Dr. Steve Rosenberg at NCI. He published research in the field of DNA vaccines while at MDNI (affiliated with UCLA). Dr. Ying was also a scientific co-founder of several biotech companies in the field of cell therapy.

Dr. Ying received a Ph.D from Stanford University, in California.

Dr. Jay Zhang joined Panacea Venture in 2018 as a Venture Partner.  He is the Co-Founder & CEO of TriArm Therapeutics and Interim CEO of Tactiva Therapeutics.  He previously was General Manager of Dragonboat Biopharmaceutical, and the Founding CEO of Dragon Sail Biopharmaceuticals.  He led the R&D, business development, IND registration & clinical trial, manufacturing setup & construction, merger & acquisition.

Jay also worked as Senior Scientist, Associate Director, Director, Founder etc. in various biotech companies including NYU Medical Center, GenMetrics, Infogene, Hyseq Pharmaceuticals, Protogene Laboratories, Anesiva etc.

Jay received a PhD in Neuroscience/Genomics from the University of Utah and did his post-doctoral training in Genetics at Stanford University. Jay is based in Shanghai, Taipei and San Francisco Bay Area.